GLP-1 Medications (Ozempic, Wegovy, Zepbound) and Sleep Apnea

Quick answer: GLP-1 receptor agonists (Ozempic, Wegovy) and the dual GLP-1/GIP agonist tirzepatide (Mounjaro, Zepbound) reduce obstructive sleep apnea severity primarily through weight loss. In December 2024, the FDA approved Zepbound specifically for moderate-to-severe OSA in adults with obesity, the first medication ever approved for OSA. A confirmed diagnosis from a sleep study is required before treatment.

The intersection of GLP-1 medications and sleep medicine changed in December 2024. Zepbound (tirzepatide) became the first prescription drug FDA-approved specifically for obstructive sleep apnea in adults with obesity. The trial that earned the approval (SURMOUNT-OSA) showed that patients on tirzepatide reduced their apnea-hypopnea index by an average of 25 events per hour at one year. That is a clinically meaningful effect.

What this means for patients and what is still misunderstood: this article walks through who qualifies, how the medications work for OSA, why a sleep study is still the first step, and where these treatments fit alongside CPAP.

How do GLP-1 medications affect sleep apnea?

Most of the OSA benefit comes from weight loss. Obesity is the single largest modifiable risk factor for OSA, a 5% to 10% loss of body weight reduces AHI by roughly 25% to 50% in many patients. GLP-1 medications produce 12% to 22% weight loss on average over 1 to 2 years, which is more than most lifestyle programs achieve.

There may also be a smaller direct effect on upper airway muscle tone and inflammation, but the dominant mechanism is straightforward: less weight on the chest and around the throat means fewer airway collapses per hour.

Who qualifies for Zepbound for OSA?

FDA labeling for the new OSA indication is specific. To qualify under the labeled indication:

• Adult (18 or older)
• Diagnosed with moderate to severe obstructive sleep apnea (AHI of 15 or higher on a polysomnography or home sleep test)
• Body mass index of 30 or higher (obesity)
• Plus the standard tirzepatide cautions: no personal or family history of medullary thyroid carcinoma or MEN 2, no severe gastroparesis, etc.

Patients with mild OSA, normal weight, or central sleep apnea aren't in the labeled population. Off-label use happens in clinical practice but insurance coverage for off-label use is uncertain.

Do I still need a sleep study?

Yes. The FDA approval requires a confirmed OSA diagnosis with a measured AHI before starting Zepbound for sleep apnea. Insurance prior authorization will require a sleep study report. This is true whether the test is in-lab polysomnography or a home sleep test, both produce the AHI that the labeling requires.

If you are already on a GLP-1 medication for diabetes or general weight loss and you haven't been tested for OSA, the testing step is still worth doing. Documenting the diagnosis at a known severity sets a baseline you can measure treatment response against.

How does this fit with CPAP?

GLP-1 therapy and CPAP aren't interchangeable. CPAP works tonight, it eliminates apnea events as soon as you wear it. GLP-1 weight loss is gradual, and AHI improvement follows weight loss with a lag. Most clinical pathways look like this:

• Diagnose OSA with a sleep test (home or in-lab)
• Start CPAP for immediate symptom relief and cardiovascular protection
• Concurrently start tirzepatide if the patient qualifies and wants weight loss
• After 6 to 12 months, repeat the sleep study to measure new AHI
• If AHI is below 5, consider weaning off CPAP under physician supervision

Some patients reach normal AHI on tirzepatide alone and stop CPAP. Some retain residual OSA and stay on combination therapy. Some achieve weight loss but don't see proportionate AHI improvement. The repeat sleep study is what tells you which path applies.

What about Ozempic and Wegovy?

Ozempic and Wegovy are both semaglutide. Wegovy is FDA-approved for chronic weight management in adults with obesity; Ozempic is approved for type 2 diabetes. Neither is FDA-approved specifically for OSA. The mechanism is the same as tirzepatide (GLP-1 receptor agonism), and the OSA benefit follows from weight loss.

If you are on semaglutide for another indication and you also have OSA, you will likely see improvement. If you want medication specifically for OSA and aren't yet on a GLP-1, tirzepatide is the medication with the labeled indication.

How do I get tested?

Talk to your primary care physician or a sleep medicine clinic about ordering a home sleep test. Advanced Sleep Medicine Services ships FDA-approved devices anywhere in California, results back to your physician within a few days. Most California insurance plans cover the test. Call (877) 775-3377 to verify your coverage.